PriceTargets.com logo

Adverum Biotechnologies - ADVM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $27.83
  • Forecasted Upside: 786.41%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.14 As of 04/15/2025 02:51 PM ET
▼ -0.29 (-8.45%)

This chart shows the closing price for ADVM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMarApr$3.43Closing price on 04/14/25:
Get New Adverum Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADVM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADVM

Analyst Price Target is $27.83
▲ +786.41% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Adverum Biotechnologies in the last 3 months. The average price target is $27.83, with a high forecast of $40.00 and a low forecast of $10.00. The average price target represents a 786.41% upside from the last price of $3.14.

This chart shows the closing price for ADVM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/254/26$2.33$12$21$31$40Closing price on 04/14/25: $3.43High$40.00Average$27.83Low$10.00




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in Adverum Biotechnologies. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/14/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2025

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
11/5/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$12.00 ➝ $10.00
8/14/2024Truist FinancialLower TargetBuy ➝ Buy$60.00 ➝ $40.00
8/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
8/13/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$15.00 ➝ $12.00
7/18/2024Chardan CapitalBoost TargetBuy ➝ Buy$4.00 ➝ $40.00
6/25/2024OppenheimerInitiated CoverageOutperform$25.00
5/15/2024Truist FinancialReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$30.00
4/30/2024HC WainwrightInitiated CoverageBuy$30.00
4/29/2024MizuhoLower TargetBuy ➝ Buy$40.00 ➝ $22.00
3/19/2024Chardan CapitalReiterated RatingBuy ➝ Buy$4.00
2/6/2024MizuhoBoost TargetBuy ➝ Buy$20.00 ➝ $40.00
11/2/2023MizuhoInitiated CoverageBuy$20.00
9/5/2023Truist FinancialReiterated RatingBuy ➝ Buy$60.00
8/11/2023Chardan CapitalUpgradeNeutral ➝ Buy$20.00 ➝ $40.00
3/7/2023LADENBURG THALM/SH SHInitiated CoverageBuy$20.00
11/11/2022Chardan CapitalLower TargetNeutral$25.00 ➝ $20.00
11/11/2022Royal Bank of CanadaLower TargetSector Perform$50.00 ➝ $30.00
8/12/2022Chardan CapitalLower TargetNeutral$30.00 ➝ $25.00
7/7/2022Truist FinancialUpgradeHold ➝ Buy$30.00 ➝ $40.00
4/11/2022Chardan CapitalReiterated RatingNeutral
10/12/2021Leerink PartnersReiterated RatingHold
7/30/2021Royal Bank of CanadaReiterated RatingHold$60.00
7/23/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral
7/23/2021Leerink PartnersLower TargetMarket Perform$50.00 ➝ $20.00
7/23/2021Chardan CapitalLower TargetNeutral$50.00 ➝ $30.00
7/23/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$230.00 ➝ $30.00
7/1/2021Chardan CapitalReiterated RatingNeutral
5/10/2021Leerink PartnersReiterated RatingOutperform ➝ Market Perform$50.00
5/5/2021Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$60.00
5/5/2021Truist FinancialReiterated RatingBuy ➝ Hold$300.00 ➝ $90.00
5/5/2021Chardan CapitalReiterated RatingBuy ➝ Neutral$200.00 ➝ $50.00
5/3/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$50.00
4/29/2021Lifesci CapitalDowngradeOutperform ➝ Market Perform
4/29/2021Chardan CapitalDowngradeBuy ➝ Neutral$200.00 ➝ $50.00
4/29/2021Truist FinancialDowngradeBuy ➝ Hold$300.00 ➝ $90.00
4/29/2021Leerink PartnersLower TargetOutperform$210.00 ➝ $110.00
4/29/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$60.00
3/2/2021Cantor FitzgeraldReiterated RatingOverweight
12/15/2020UBS GroupInitiated CoverageNeutral$130.00
11/12/2020Raymond JamesUpgradeUnderperform ➝ Market Perform
11/5/2020Lifesci CapitalReiterated RatingOutperform
8/26/2020Raymond JamesReiterated RatingHold
8/11/2020Leerink PartnersBoost TargetOutperform$200.00 ➝ $210.00
8/10/2020Piper SandlerBoost TargetOverweight$250.00 ➝ $300.00
7/8/2020Cantor FitzgeraldBoost TargetOverweight$210.00 ➝ $360.00
6/26/2020Raymond JamesDowngradeMarket Perform ➝ Underperform
6/16/2020Royal Bank of CanadaBoost TargetPositive ➝ Outperform$240.00 ➝ $300.00
5/30/2020Chardan CapitalReiterated RatingBuy
5/29/2020Piper SandlerBoost Target$200.00 ➝ $250.00
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$240.00
5/8/2020Chardan CapitalReiterated RatingBuy$200.00
5/5/2020Leerink PartnersBoost TargetOutperform$170.00 ➝ $200.00
5/5/2020SunTrust BanksUpgradeHold ➝ Buy$130.00 ➝ $210.00
4/28/2020The Goldman Sachs GroupInitiated CoverageBuy$170.00
(Data available from 4/15/2020 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/17/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/17/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/16/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/16/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/15/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/14/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/16/2025
  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/15/2025

Current Sentiment

  • 9 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Adverum Biotechnologies logo
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $3.14
Low: $3.14
High: $3.71

50 Day Range

MA: $4.31
Low: $3.33
High: $5.60

52 Week Range

Now: $3.14
Low: $3.07
High: $12.09

Volume

53,195 shs

Average Volume

253,345 shs

Market Capitalization

$65.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Adverum Biotechnologies?

The following Wall Street research analysts have issued reports on Adverum Biotechnologies in the last twelve months: Chardan Capital, HC Wainwright, Mizuho, Oppenheimer Holdings Inc., Royal Bank of Canada, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for ADVM.

What is the current price target for Adverum Biotechnologies?

0 Wall Street analysts have set twelve-month price targets for Adverum Biotechnologies in the last year. Their average twelve-month price target is $27.83, suggesting a possible upside of 786.4%. Truist Financial Co. has the highest price target set, predicting ADVM will reach $40.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $10.00 for Adverum Biotechnologies in the next year.
View the latest price targets for ADVM.

What is the current consensus analyst rating for Adverum Biotechnologies?

Adverum Biotechnologies currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ADVM.

What other companies compete with Adverum Biotechnologies?

Other companies that are similar to Adverum Biotechnologies include Cryoport, COMPASS Pathways, Olema Pharmaceuticals, Arcturus Therapeutics and Aura Biosciences. Learn More about companies similar to Adverum Biotechnologies.

How do I contact Adverum Biotechnologies' investor relations team?

Adverum Biotechnologies' physical mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company's listed phone number is (650) 656-9323 and its investor relations email address is mlacy@adverum.com. The official website for Adverum Biotechnologies is www.adverum.com. Learn More about contacing Adverum Biotechnologies investor relations.





Receive Adverum Biotechnologies News & Ratings Daily
Sign up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with PriceTargets.com’s free daily newsletter.